Campise M, Tarantino A, Berardinelli L, Finazzi S, Montagnino G, Rossini G, Scalamogna M, Cesana B, Ponticelli C
Dipartimento di Nefrourologia e Trapianto Renale, Italy.
G Ital Nefrol. 2002 Jan-Feb;19(1):49-54.
Renal transplantation is the best possibile form of treatment for chronic renal failure. It offers the patient a longer life expectancy when compared to dialysis. Aim of the study was to evaluate our results with live donor transplantation and the variables that influenced the long-term patient and graft survival.
190 patients received a live donor kidney transplantation in our Hospital between 1984 and 2000. Thirty-eight of them received a graft from an HLA identical donor, 130 from an HLA haploidentical donor, 22 from a living unrelated donor (spouse). Fourteen patients underwent a pre-emptive transplantation. Aim of the study was to evaluate which variables could influence the long-term patient and graft survival.
The median follow-up of recipients was 69.5 months. The 10-year patient and graft survival were 94.7% and 73.4% respectively. Graft half-life was 29.6 years. Six patients died. Twelve patients lost their graft because of vascular thrombosis and five patients because of rejection within the first six months. After the first year, 11 patients lost their graft because of chronic rejection and 4 after recurrence of the original disease. One hundred and forty-four patients are still under observation, and at the last examination their mean plasma creatinine was 2.0+/-1.1 mg/dl. At univariate statistical analysis the absence of locus DR incompatibility was associated with a trend toward a better long-term survival of both patient and graft (P=0.05), while less than one year of dialysis showed a significantly better survival rate (P < 0.01).
Living-donor transplantation offers an excellent long-term patient and graft survival.
肾移植是慢性肾衰竭最佳的治疗方式。与透析相比,它能让患者预期寿命更长。本研究的目的是评估我们活体供肾移植的结果以及影响患者和移植物长期存活的变量。
1984年至2000年间,190例患者在我院接受了活体供肾移植。其中38例接受了来自HLA全相同供者的移植物,130例接受了来自HLA半相同供者的移植物,22例接受了来自活体非亲属供者(配偶)的移植物。14例患者接受了 preemptive 移植。本研究的目的是评估哪些变量会影响患者和移植物的长期存活情况。
受者的中位随访时间为69.5个月。10年患者和移植物存活率分别为94.7%和73.4%。移植物半衰期为29.6年。6例患者死亡。12例患者因血管血栓形成失去移植物,5例患者在头6个月内因排斥反应失去移植物。1年后,11例患者因慢性排斥反应失去移植物,4例患者在原发病复发后失去移植物。144例患者仍在观察中,在最后一次检查时,他们的平均血浆肌酐为2.0±1.1mg/dl。单因素统计分析显示,DR位点不相容的缺失与患者和移植物长期存活更好的趋势相关(P = 0.05),而透析时间少于1年的患者存活率显著更高(P < 0.01)。
活体供肾移植能带来出色的患者和移植物长期存活情况。